Abcam, ab308065, Anti-FCRL1+FCRL2 antibody [EPR26947-62] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal FCRL2 antibody. Carrier free. Suitable for Flow Cyt, Flow Cyt (Intra) and reacts with Human, Transfected cell line - Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR26947-62,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:Flow Cyt (Intra), Flow CytSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FCRL1 and FCRL2 are proteins part of the Fc receptor-like (FCRL) family. FCRL1 also known as Fc receptor-like protein 1 is a membrane-bound protein weighing approximately 98 kDa. It is mainly expressed on mature B lymphocytes. FCRL2 also known as Fc receptor-like protein 2 has an estimated mass of 100 kDa and is also found on B cells but at varying levels depending on the cell's stage and condition. Expression of these receptors occurs principally within the immune system hinting at their regulatory roles in immune responses.
Biological function summary
These proteins are integral to immune function. FCRL1 participates in the regulation of B cell activation and antibody production while FCRL2 modulates B cell responses during immune processes. Both proteins can interact with various immunoglobulins suggesting their role in modulating signaling pathways associated with B cell receptor activity. FCRL1 and FCRL2 appear to be components of larger regulatory complexes on the B cell surface coordinating immune response based on extracellular signals.
Pathways
FCRL1 and FCRL2 are involved in B cell signaling networks. They form important components of pathways like the B cell receptor (BCR) signaling and the immune regulation network. Both proteins are associated with other receptor proteins such as CD19 and CD21 playing a part in fine-tuning the signaling processes that influence B cell maturation and antibody responses. Their activity influences not just BCR signaling but also other related immune regulatory pathways bridging external signals and B cell functionality.
Malfunction or misregulation of FCRL1 and FCRL2 is linked with autoimmune diseases and B cell malignancies like systemic lupus erythematosus and chronic lymphocytic leukemia. These proteins when deregulated may contribute to altered B cell proliferation or inappropriate immune signaling. In these diseases the involvement of proteins like CD22 and CD40 indicates that FCRL1 and FCRL2 have broader roles in immune dysregulation impacting disease pathogenesis and progression. Understanding their function and interactions could lead to targeted therapies and better disease management.